What is it? Why is it important?
Apart from the study protocol, other study and reference documents provide study relevant safety information, such as the:
- Patient Information Sheet (PIS) / Informed Consent Form (ICF): explain expected study risks to participants including the risk-benefit of the study
- Case Report Form (CRF) / Study Database: where (serious) adverse reactions / events are documented in a standardised manner (e.g. either electronically or in paper form)
- Product Information (PI): summarises all currently known safety information on marketed MPs
- Instruction for use (IFU): summarises all currently known safety information on marketed MDs
- Investigator Brochure (IB): summarises all currently known safety information on non-marketed products (e.g. IMP, IMD)
- Monitoring plan: describes the risk-based monitoring strategy of the study (e.g. high risk studies require more extensive monitoring)
What do I need to do?
As a SP-INV ensure safety information and concerns are included in applicable study documents, such as:
- PIS / ICF: include a list of foreseeable frequent AEs sorted by frequency. For infrequent ones include only serious ones
- CRF: Irrespective whether in electronic or paper form (e.g. questionnaires), include sections for the documentation of safety events (e.g. AE / SAE / DD / SADE). Define whether SAE forms are available in electronic or paper form
- Monitoring plan: adapt your monitoring strategy based on the risk assessment of your study (e.g. high risk requires more frequent monitoring visits)
Based on your study, describe the reference documents that apply to your study (e.g. IB for IMP/IMD, SmPC / PI for marketed MP, IFU for marketed MDs). The IB must be updated on a yearly basis (e.g. by the marketing holder of the therapeutic product)
If applicable, provide participants with an “in-case-of-emergency” card. Cards should include the participant’s name, study identifier, type of intervention, an emergency contact number, and the name of the Site-INV.
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
Swissethics – see in particular
- Templates / Checklists
- Study protocols
- Patient information and consent
ICH GCP E6(R2) – see in particular guidelines
- 1.64 Monitoring plan
- 5.18 Monitoring